Allogene Therapeutics' GAAP loss for 9M 2021 was $182.137 million, up 0.3% from $181.651 million in the prior year. Revenues were $38.438 million. A year earlier the company had no revenue.
Allogene Therapeutics' GAAP loss for 9M 2021 was $182.137 million, up 0.3% from $181.651 million in the prior year. Revenues were $38.438 million. A year earlier the company had no revenue. 
ir.allogene.com
English (US) 